<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Arnold, Douglas L.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Relapsing-Remitting Multiple Sclerosis Effectively Treated with Peginterferon Beta-1</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-06-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">10-11</style></pages><abstract><style  face="normal" font="default" size="100%">Significantly more subjects with relapsing-remitting multiple sclerosis achieved freedom from measured disease activity when treated with peginterferon beta-1a every 2 weeks compared with those who were treated with peginterferon beta-1a every 4 weeks or placebo. This article presents results from a post hoc analysis of 48-week data from the Efficacy and Safety Study of BIIB017 (PEGylated Interferon Beta-1a) in Participants With Relapsing Multiple Sclerosis trial [ADVANCE; NCT00906399].</style></abstract><number><style face="normal" font="default" size="100%">6</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>